CIDEM-255

CIDEM-255 is an investigational **fixed-dose combination of amitriptyline and paracetamol** developed by Centro de Investigaciones y Desarrollo de Medicamentos for **mixed cancer pain**. The sponsor describes preclinical isobolographic studies supporting the absence of pharmacological interactions between the two active ingredients and their potential use in multimodal analgesic treatment. Amitriptyline contributes analgesic activity partly through inhibition of serotonin and norepinephrine reuptake, while paracetamol provides centrally mediated non-opioid analgesia; the exact molecular mechanism responsible for paracetamol analgesia remains incompletely defined.

Other names

amitriptyline + paracetamolparacetamol + amitriptyline